Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial
2017 · The Lancet · 197 citations
https://doi.org/10.1016/s0140-6736(17)30930-3
V
Vivek Pradhan
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
67
Papers
754
Citations
15
h-index
18
i10-index
Vivek Pradhan is an academic researcher from Pfizer (United States). The author has contributed to research in topics: Statistical Methods and Bayesian Inference & Inflammatory Bowel Disease & Statistical Methods in Clinical Trials. The author has an h-index of 15, co-authored 57 publications.
ORCID: 0000-0003-4590-5383Papers by this author
worksDimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2024 · Nature Communications · 8 citations
https://doi.org/10.1038/s41467-023-43644-x
Comparative prospective study of proximal femoral nail and locking compression plate in subtrochanteric fractures of femur
2018 · National Journal of Clinical Orthopaedics · 5 citations
https://doi.org/10.33545/orthor.2018.v2.i4c.94
Ritlecitinib, a JAK3 /TEC inhibitor, modulates the markers of celiac autoimmunity in alopecia areata and vitiligo patients
2025 · Archives of Dermatological Research · 3 citations
https://doi.org/10.1007/s00403-024-03784-6
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat